Biennial screening mammography is cost effective in healthy women aged over 65 years

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Question. What is the cost-effectiveness of screening mammography in women over 65 years old? Study design. Systematic review with narrative synthesis. Main results. Ten studies, out of 115 identified, met inclusion criteria. Studies had similar cost-effectiveness findings; extending biennial screening to ages 75-80 years cost, on average, $34,000-$88,000 per life year gained compared with stopping screening at age 65 (adjusted to 2002 US dollars). Two studies found breast cancer screening less effective at reducing mortality in women with significant comorbidities (dementia, congestive heart failure, or hypertension), thus reducing the cost-effectiveness of screening in this population. No study fully adjusted for potential harms of screening. Authors' conclusions. In women aged over 65 years without serious comorbidity, biennial breast cancer screening reduces mortality at reasonable costs.

Original languageEnglish (US)
Pages (from-to)142-144
Number of pages3
JournalEvidence-Based Healthcare
Volume8
Issue number3
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Mammography
Cost-Benefit Analysis
Early Detection of Cancer
Costs and Cost Analysis
Comorbidity
Breast Neoplasms
Mortality
Dementia
Heart Failure
Hypertension
Population

Keywords

  • Breast cancer
  • Cost-effectiveness
  • Elderly
  • Mammography
  • Mass screening
  • Systematic review

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biennial screening mammography is cost effective in healthy women aged over 65 years. / Carney, Patricia (Patty).

In: Evidence-Based Healthcare, Vol. 8, No. 3, 06.2004, p. 142-144.

Research output: Contribution to journalArticle

@article{b233a26a94b44450b2dbe7392d2efb7f,
title = "Biennial screening mammography is cost effective in healthy women aged over 65 years",
abstract = "Question. What is the cost-effectiveness of screening mammography in women over 65 years old? Study design. Systematic review with narrative synthesis. Main results. Ten studies, out of 115 identified, met inclusion criteria. Studies had similar cost-effectiveness findings; extending biennial screening to ages 75-80 years cost, on average, $34,000-$88,000 per life year gained compared with stopping screening at age 65 (adjusted to 2002 US dollars). Two studies found breast cancer screening less effective at reducing mortality in women with significant comorbidities (dementia, congestive heart failure, or hypertension), thus reducing the cost-effectiveness of screening in this population. No study fully adjusted for potential harms of screening. Authors' conclusions. In women aged over 65 years without serious comorbidity, biennial breast cancer screening reduces mortality at reasonable costs.",
keywords = "Breast cancer, Cost-effectiveness, Elderly, Mammography, Mass screening, Systematic review",
author = "Carney, {Patricia (Patty)}",
year = "2004",
month = "6",
doi = "10.1016/j.ehbc.2004.03.015",
language = "English (US)",
volume = "8",
pages = "142--144",
journal = "Evidence-Based Healthcare",
issn = "1462-9410",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Biennial screening mammography is cost effective in healthy women aged over 65 years

AU - Carney, Patricia (Patty)

PY - 2004/6

Y1 - 2004/6

N2 - Question. What is the cost-effectiveness of screening mammography in women over 65 years old? Study design. Systematic review with narrative synthesis. Main results. Ten studies, out of 115 identified, met inclusion criteria. Studies had similar cost-effectiveness findings; extending biennial screening to ages 75-80 years cost, on average, $34,000-$88,000 per life year gained compared with stopping screening at age 65 (adjusted to 2002 US dollars). Two studies found breast cancer screening less effective at reducing mortality in women with significant comorbidities (dementia, congestive heart failure, or hypertension), thus reducing the cost-effectiveness of screening in this population. No study fully adjusted for potential harms of screening. Authors' conclusions. In women aged over 65 years without serious comorbidity, biennial breast cancer screening reduces mortality at reasonable costs.

AB - Question. What is the cost-effectiveness of screening mammography in women over 65 years old? Study design. Systematic review with narrative synthesis. Main results. Ten studies, out of 115 identified, met inclusion criteria. Studies had similar cost-effectiveness findings; extending biennial screening to ages 75-80 years cost, on average, $34,000-$88,000 per life year gained compared with stopping screening at age 65 (adjusted to 2002 US dollars). Two studies found breast cancer screening less effective at reducing mortality in women with significant comorbidities (dementia, congestive heart failure, or hypertension), thus reducing the cost-effectiveness of screening in this population. No study fully adjusted for potential harms of screening. Authors' conclusions. In women aged over 65 years without serious comorbidity, biennial breast cancer screening reduces mortality at reasonable costs.

KW - Breast cancer

KW - Cost-effectiveness

KW - Elderly

KW - Mammography

KW - Mass screening

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=13244250973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244250973&partnerID=8YFLogxK

U2 - 10.1016/j.ehbc.2004.03.015

DO - 10.1016/j.ehbc.2004.03.015

M3 - Article

AN - SCOPUS:13244250973

VL - 8

SP - 142

EP - 144

JO - Evidence-Based Healthcare

JF - Evidence-Based Healthcare

SN - 1462-9410

IS - 3

ER -